We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal judge rejected AstraZeneca’s motion to block generics from making versions of its inhaled corticosteroid Pulmicort Respules, and instead will consider that request and broader patent issues on the drug when the trial resumes this fall. Read More
A federal judge tossed out claims over a patent in Sandoz’s bid to launch a generic version of United Therapeutics Corporation’s pulmonary arterial hypertension drug Remodulin, but two more patent challenges remain. Read More
British drugmaker GlaxoSmithKline has agreed to pay $105 million to 44 states and the District of Columbia to settle allegations it engaged in deceptive marketing and sales practices on its asthma drug Advair Diskus and antidepressants Wellbutrin and Paxil. Read More
Drugmakers considering names for new products in Europe will have to narrow their options to just two proposed names under a revised guideline from the European Medicines Agency. Read More
Germany-based Sandoz has launched a generic version of Lundbeck’s antidepressant Cipralex in Belgium, France, Germany, Italy, Sweden and Switzerland, the generic firm said. Read More
The City of Chicago has sued five manufacturers of opioid painkillers, alleging the firms improperly marketed the addictive drugs for chronic, non-cancer-related pain management, a practice that elevated the city’s addiction rate and resulted in millions of dollars of unnecessary payments. Read More
Alexion is pulling more of its flagship product Soliris from the market due to visible particles that arose from a manufacturing problem, its third recall in less than a year. Read More
Pfizer has agreed to pay $325 million to private insurers to settle a decade-old lawsuit alleging the drug giant illegally marketed the epilepsy drug Neurontin for off-label purposes. Read More